Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 2250-2266

  Manzano, Ramon G ^a   Martinez Navarro, Elena M ^a   Forteza, Jeronimo ^a,b,c   Brugarolas, Antonio ^a  

^a HOSPITAL QUIRÓN   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

Author keywords

Breast cancer; DUSP4; DUSP6; MAPK; Microarray; Phosphatase; Phosphatome; PI3K; Profiling

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 6; DUSP4 PROTEIN, HUMAN; DUSP6 PROTEIN, HUMAN; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; AGED; BIOSYNTHESIS; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MICROARRAY ANALYSIS; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DUAL SPECIFICITY PHOSPHATASE 6; DUAL-SPECIFICITY PHOSPHATASES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROARRAY ANALYSIS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROGNOSIS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 84907684933     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2648     Document Type: Article

References (36)

1. Moorhead GB, Trinkle-Mulcahy L and Ulke-Lemee A: Emerging roles of nuclear protein phosphatases. Nat Rev Mol Cell Biol 8:234-244, 2007.
2. Julien SG, Dube N, Hardy S and Tremblay ML: Inside the human cancer tyrosine phosphatome. Nat Rev Cancer 11:35-49, 2011.
3. Vicent S, Garayoa M, Lopez-Picazo JM, et al: Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin Cancer Res 10:3639-3649, 2004.
4. Manzano RG, Montuenga LM, Dayton M, et al: CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene 21:4435-4447, 2002.
5. Smyth GK and Speed T: Normalization of cDNA microarray data. Methods 31:265-273, 2003.
6. Desmedt C, Piette F, Loi S, et al: Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13:3207-3214, 2007.
7. Shi L, Campbell G, Jones WD, et al: The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 28:827-838, 2010.
8. Wang Y, Klijn JG, Zhang Y, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679, 2005.
9. van de Vijver MJ, V, He YD, Van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002.
10. Parikh JR, Klinger B, Xia Y, Marto JA and Bluthgen N: Discovering causal signaling pathways through gene-expression patterns. Nucleic Acids Res 38: W109-W117, 2010.
11. Subramanian A, Tamayo P, Mootha VK, et al: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545-15550, 2005.
12. Bair E and Tibshirani R: Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2: E108, 2004.
13. Montojo J, Zuberi K, Rodriguez H, et al: GeneMANIA Cytoscape plugin: fast gene function predictions on the desktop. Bioinformatics 26:2927-2928, 2010.
14. Mostafavi S, Ray D, Warde-Farley D, Grouios C and Morris Q: GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function. Genome Biol 9(Suppl 1):S4, 2008.
15. Warde-Farley D, Donaldson SL, Comes O, et al: The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res 38: W214-W220, 2010.
16. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000.
17. Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009.
18. Hu Z, Fan C, Oh DS, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7:96, 2006.
19. Gewinner C, Wang ZC, Richardson A, et al: Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 16:115-125, 2009.
20. Fedele CG, Ooms LM, Ho M, et al: Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci USA 107:22231-22236, 2010.
21. Marty B, Maire V, Gravier E, et al: Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 10: R101, 2008.
22. Hu X, Stern HM, Ge L, et al: Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 7:511-522, 2009.
23. Lopez-Knowles E, O'Toole SA, McNeil CM, et al: PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 126:1121-1131, 2010.
24. Wang Q, Diskin S, Rappaport E, et al: Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 66:6050-6062, 2006.
25. Nakayama R, Nemoto T, Takahashi H, et al: Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol 20:749-759, 2007.
26. Nunes-Xavier CE, Elson A and Pulido R: Epidermal growth factor receptor (EGFR)-mediated positive feedback of proteintyrosine phosphatase epsilon (PTPepsilon) on ERK1/2 and AKT protein pathways is required for survival of human breast cancer cells. J Biol Chem 287:3433-3444, 2012.
27. Bermudez O, Pages G and Gimond C: The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol 299: C189-C202, 2010.
28. Aguirre-Gamboa R, Gomez-Rueda H, Martinez-Ledesma E, et al: SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One 8: e74250, 2013.
29. Lucci MA, Orlandi R, Triulzi T, Tagliabue E, Balsari A and Villa-Moruzzi E: Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. Cell Oncol 32:361-372, 2010.
30. Revillion F, Puech C, Rabenoelina F, Chalbos D, Peyrat JP and Freiss G: Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer. Int J Cancer 124:638-643, 2009.
31. Jing J, Greshock J, Holbrook JD, et al: Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther 11:720-729, 2012.
32. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM and El-Ashry D: Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 66:3903-3911, 2006.
33. Berns K, Horlings HM, Hennessy BT, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402, 2007.
34. Will M, Qin AC, Toy W, et al: Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov 4:334-347, 2014.
35. Huang E, Cheng SH, Dressman H, et al: Gene expression predictors of breast cancer outcomes. Lancet 361:1590-1596, 2003.
36. Balko JM, Cook RS, Vaught DB, et al: Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 18:1052-1059, 2012.